Deterioration in acute ischemic stroke as the target for neuroprotection

Cerebrovascular Diseases

Volumn 21, Issue SUPPL. 2, 2006, Pages 80-88

  Serena, Joaquín ^a   Rodríguez Yáñez, Manuel ^b   Castellanos, Mar ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Acute ischemic stroke; Early neurological deterioration; Excitotoxicity; Glutamate; Progressing stroke

Indexed keywords

ALTEPLASE; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

CEREBROVASCULAR ACCIDENT; DISEASE COURSE; EXCITOTOXICITY; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; STROKE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY TEMPERATURE; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COLLATERAL CIRCULATION; CYTOKINES; DISEASE PROGRESSION; ENCEPHALITIS; GLUTAMIC ACID; HUMANS; NEUROPROTECTIVE AGENTS; STROKE;

EID: 33646481507     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091707     Document Type: Review

References (50)

1. Jones HJ, Millikan CH: Temporal profile (clinical course) of acute carotid system cerebral infarction. Stroke 1976;7:64-71.
2. Patrick BK, Ramirez-Lassepas M, Synder BD: Temporal profile of vertebrobasilar territory infarction. Prognostic implications. Stroke 1980;11:643-648.
3. Jones HR Jr, Millikan CH, Sandok BA: Temporal profile (clinical course) of acute vertebrobasilar system cerebral infarction. Stroke 1980;11:173-177.
4. Britton M, Roden A: Progression of stroke after arrival at hospital. Stroke 1985;16:629-632.
5. Lodder J, Gorsselink EL: Progressive stroke caused by CT-verified small deep infarcts; relation with the size of the infarct and clinical outcome. Acta Neurol Scand 1985;71:328-330.
6. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS: Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344:156-159.
7. Toni D, Fiorelli M, Gentile M, Bastianello S, Sacchetti ML, Argentino C, Pozzilli C, Fieschi C: Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis. Arch Neurol 1995;52:670-675.
8. Dávalos A, Castillo J, Pumar JM, Noya M: Body temperature and fibrinogen are related to early neurological deterioration in acute ischemic stroke. Cerebrovasc Dis 1997;7:64-69.
9. Hachinski V, Norris JW: The deteriorating stroke; in Meyer JS Lechner H, Reivich M, Ott EO, Aranibar A (eds): 10th International Salzburg Conference on Cerebral Vascular Disease, Salzburg, Sept 1980. Amsterdam, Excerpta Medica, 1980, pp 315-318.
10. Davalos A, Cendra E, Teruel J, Martinez M, Genis D: Deteriorating ischemic stroke: risk factors and prognosis. Neurology 1990;40:1865-1869.
11. Toni D, Fiorelli M, Zanette EM, Sacchetti ML, Salerno A, Argentino C, Solaro M, Fieschi C: Early spontaneous improvement and deterioration of ischemic stroke patients. A serial study with transcranial Doppler ultrasonography. Stroke 1998;29:1144-1148.
12. Yamamoto, H, Bogousslavsky J, van Melle G: Different predictors of neurological worsening in different causes of stroke. Arch Neurol 1998;55:481-486.
13. Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A: Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poorstroke outcome. Stroke 2004;35:520-527.
14. Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J for the ECASS Group: Neurological deterioration in acute ischemic stroke. Potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke 1999;30:2631-2636.
15. Serena J, Leira R, Castillo, Pumar JM, Castellanos M, Dávalos A: Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke 2001;32:1154-1161.
16. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A: Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002;33:982-987.
17. Leira R. Dávalos A, Aneiros A, Serena J, Pumar JM, Castillo J: Headache as a surrogate marker of the molecular mechanisms implicated in progressing stroke. Cephalalgia 2002;22:303-308.
18. Millikan CH, Siekert RG: Studies in cerebrovascular disease. I. The syndrome of intermittent insufficiency of the basilar arterial system. Mayo Clin Proc 1955;30:61-68.
19. Castillo J: Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment. Cerebrovasc Dis 1999;9(suppl 3):1-8.
20. Nakamura K, Saku Y, Ibayashi S, Fujishima M: Progressive motor deficits in lacunar infarction. Neurology 1999;52:29-33.
21. Castillo J, Rama R, Dávalos A: Nitric oxide-related brain damage in acute ischemic stroke. Stroke 2000;31:852-857.
22. Castillo J, Dávalos A, Noya M: Progression of ischemic stroke and excitotoxic amino acids. Lancet 1997;349:79-83.
23. Dávalos A, Castillo J, Marrugat J, Fernández-Real JM, Armengou A, Cacabelos P, Rama R: Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology 2000;54:1568-1574.
24. Berger L, Hakim AM: The association of hyperglycemia with cerebral edema in stroke. Stroke 1986;17:865-871.
25. Toni D, De Michele M, Fiorelli M, Bastianello S, Camerlingo M, Sacchetti ML, Argentino C, Fieschi C: Influence of hyperglycaemia on infarct size and clinical outcome of acute ischemic stroke patients with intracranial arterial occlusion. J Neurol Sci 1994;123:129-133.
26. Craven TE, Ryu JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, McMahan MR, Thompson CJ, Heiss G, Crouse JR: Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case-control study. Circulation 1990;82:1230-1242.
27. Derdeyn CP, Grubb RL, Powers WJ: Cerebral hemodynamic impairment. Methods of measurement and association with stroke risk. Neurology 1999;53:251-259.
28. Kaps M, Teschendorf U, Dorndorf W: Hemodynamic studies in early stroke. J Neurol 1992;239:138-142.
29. Rubin G, Firlik A, Levy E, Pindzola R, Yonas H: Relationship between cerebral blood flow and clinical outcome in acute stroke. Cerebrovasc Dis 2000;10:298-306.
30. Alexandrov AV, Demchuk A, Wein T, Grotta JC: The yield of transcranial Doppler in acute cerebral ischemia. Stroke 1999;30:1604-1609.
31. Álvarez FJ, Segura T, Castellanos M, Leira R, Blanco M, Dávalos A, Serena J: Cerebral hemodynamic reserve and early neurologic deterioration in acute ischemic stroke. J Cereb Blood Flow Metab 2004:2004;24:1267-1271.
32. 2-induced cerebral vasomotor response in normal individuals and patients with internal carotid artery occlusions. Stroke 1998;19:963-969.
33. Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Dávalos A: The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005;36:1921-1926.
34. De Cristobal J, Moro MA, Davalos A, Castillo J, Leza JC, Camarero J, Colado MI, Lorenzo P, Lizasoain I: Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischaemia in rats. J Neurochem 2001;79:456-459.
35. Castillo J, Leira R, Moro MA, Lizasoain I, Serena J, Dávalos A: Neuroprotective effects of aspirin in patients with acute cerebral infarction. Neurosci Lett 2003;339:248-250.
36. Grotta JC, Lemak NA, Gary H, Fields WS, Vital D: Does platelet antiaggregant therapy lessen the severity of stroke? Neurology 1985;35:632-636.
37. Takagi K, Ginsberg MD, Globuls MYT, Dietrich WD, Martinez E, Kraydieh S, Busto R: Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbra region following middle cerebral artery occlusion in the rat: correlation with histopathology. J Cereb Blood Flow Metab 1993;13:575-585.
38. Butcher SP, Bullock R, Graham DI, McCulloch J: Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 1990;21:1727-1733.
39. Dávalos A, Castillo J, Serena J, Noya M: Duration of glutamate release after acute ischemic stroke. Stroke 1997;28:708-710.
40. Dávalos A, Castillo J: Potential mechanisms of worsening. Cerebrovasc Dis 1997;7(suppl 5):19-24.
41. Rothman SM, Olney JW: Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-111.
42. Castillo J, Leira R: Predictors of deteriorating cerebral infarct: role of inflammatory mechanisms. Would its early treatment be useful? Cerebrovasc Dis 2001;11(suppl 1):40-48.
43. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-397.
44. Castillo J, Davalos A, Naveiro J, Noya M: Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996;27:1060-1065.
45. Castillo J, Dávalos A, Lema M, Serena J, Noya M: Glutamate is a marker for cerebral ischemia in cortical but not deep infarcts. Cerebrovasc Dis 1997;7:245-250.
46. Castellanos M, Blanco M, Pedraza S, García M, Silva Y, Leira R, Dávalos A: Molecular markers of progressing stroke are associated with diffusion-weighted MRI lesion growth in patients with acute ischemic stroke. Stroke 2004;35:247.
47. Seal RP, Amara SG: Excitatory amino acid transporters: a family in flux. Annu Rev Pharmacol Toxicol 1999;39:431-456.
48. Mallolas J, Hurtado O, Castellanos M, Blanco M, Rodríguez- Yáñez M, Puigdemont M, Serena J, Pedraza S, Moro MA, Lizasoain I, Castillo J, Davalos A: A novel functional polymorphism in the EAAT2 gene is associated with higher glutamate concentrations and brain injury. Stroke 2005;36:458.
49. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A: Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003;34:671-675.
50. Blanco M, Moro MA, Dávalos A, Leira R, Castellanos M, Serena J, Vivancos J, Rodríguez-Yáñez M, Lizasoain I, Castillo J: Increased plasma levels of 15-deoxy δ prostaglandin j2 are associated with good outcome in acute atherothrombotic ischemic stroke. Stroke 2005;36:1189-1194.